Described is an aqueous calcium gluconate solution formulated without calcium saccharate, which can be stored in a flexible plastic bag and can be terminally sterilized.

Described is an aqueous calcium gluconate solution formulated without calcium saccharate, which can be stored in a flexible plastic bag and can be terminally sterilized.

A silybin injection contains silybin, sulfobutyl ether-β-cyclodextrin, an organic solvent for injection and may further contain a co-solvent, a lyophilization proppant, a pH regulator, water for injection and the like.

Method for the treatment of virus infection with IVIG and convalescent plasma. Methods and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof, including administering to the patient a therapeutically effective amount of intravenous Immunoglobulin G (IVIG) in an amount of about 0.5 g/kg to about 8 g/kg. Methods and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof, including administering to the patient a therapeutically effective amount of convalescent anti-SARS-CoV-2 plasma, wherein the convalescent anti-SARS-CoV-2 plasma is treated with methylene blue for pathogen inactivation.

Method for the treatment of virus infection with IVIG and convalescent plasma. Methods and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof, including administering to the patient a therapeutically effective amount of intravenous Immunoglobulin G (IVIG) in an amount of about 0.5 g/kg to about 8 g/kg. Methods and compositions for the treatment of coronavirus disease 2019 (COVID-19) in a patient in need thereof, including administering to the patient a therapeutically effective amount of convalescent anti-SARS-CoV-2 plasma, wherein the convalescent anti-SARS-CoV-2 plasma is treated with methylene blue for pathogen inactivation.

A general serum procedure for all of pathogens with protein coding on an outer shell of the pathogens, comprises entering dead pathogens and their dead genomes to eliminate pathogens and cancer genes in humans and animals. A device for detecting pathogens in human body, animals, plants, water bodies, and air without blood test observes the spectral signature emitting from the human body and the water to match for any pathogens within the device’s database and uses electrostatic properties of the pathogens and their genomes to catch them.

A general serum procedure for all of pathogens with protein coding on an outer shell of the pathogens, comprises entering dead pathogens and their dead genomes to eliminate pathogens and cancer genes in humans and animals. A device for detecting pathogens in human body, animals, plants, water bodies, and air without blood test observes the spectral signature emitting from the human body and the water to match for any pathogens within the device’s database and uses electrostatic properties of the pathogens and their genomes to catch them.

Disclosed herein is a formulation comprising an extracellular vesicle (EV), and a therapeutic active agent induced or embedded in the EV. According to preferred embodiments of the present disclosure, the EV is isolated from umbilical cord mesenchymal stem cells, and the active agent may be a growth factor, an immune-modulating agent, a small molecule, an siRNA, cDNA or a plant ingredient; for example, curcumin. Also disclosed herein are methods for producing the present formulation, and uses of the present formulation in the treatment of various diseases.

Disclosed herein is a formulation comprising an extracellular vesicle (EV), and a therapeutic active agent induced or embedded in the EV. According to preferred embodiments of the present disclosure, the EV is isolated from umbilical cord mesenchymal stem cells, and the active agent may be a growth factor, an immune-modulating agent, a small molecule, an siRNA, cDNA or a plant ingredient; for example, curcumin. Also disclosed herein are methods for producing the present formulation, and uses of the present formulation in the treatment of various diseases.

The present invention relates to a pharmaceutical composition comprising a liquid composition containing p-boronophenylalanine, in which the liquid composition is accommodated in a packaging material and satisfies the following Condition I or Condition II: Condition I: the liquid composition comprises substantially no antioxidant and a concentration of dissolved oxygen in the liquid composition is 3.5 ppm or less; Condition II: the liquid composition comprises an antioxidant and a concentration of dissolved oxygen in the liquid composition is 3.0 ppm or less.